DBV Technologies 将来の成長

Future 基準チェック /26

DBV Technologiesは、6.5%と59.6%でそれぞれ年率6.5%で利益と収益が成長すると予測される一方、EPSはdeclineで11.3%年率。

主要情報

6.5%

収益成長率

-11.3%

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	59.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	25 Oct 2024

今後の成長に関する最新情報

更新なし

Recent updates

FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial

Sep 21

DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M

Aug 01

業績と収益の成長予測

NasdaqCM:DBVT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	6	-124	-183	-119	1
12/31/2025	5	-119	-172	-114	1
12/31/2024	5	-128	-160	-110	2
9/30/2024	13	-102	-109	-106	N/A
6/30/2024	14	-88	-105	-103	N/A
3/31/2024	15	-80	-95	-94	N/A
12/31/2023	16	-73	-80	-80	N/A
9/30/2023	6	-101	-90	-90	N/A
6/30/2023	5	-101	-91	-90	N/A
3/31/2023	4	-100	-76	-75	N/A
12/31/2022	5	-96	-56	-56	N/A
9/30/2022	9	-71	-52	-51	N/A
6/30/2022	8	-77	-55	-53	N/A
3/31/2022	5	-85	-74	-74	N/A
12/31/2021	6	-98	-109	-108	N/A
9/30/2021	2	-124	-124	-123	N/A
6/30/2021	4	-131	-144	-142	N/A
3/31/2021	9	-148	-154	-152	N/A
12/31/2020	11	-160	-168	-166	N/A
9/30/2020	17	-161	-157	-153	N/A
6/30/2020	16	-171	-156	-151	N/A
3/31/2020	16	-169	-161	-156	N/A
12/31/2019	15	-172	-154	-148	N/A
9/30/2019	12	-176	-156	-151	N/A
6/30/2019	13	-198	-176	-169	N/A
3/31/2019	13	-191	-166	-160	N/A
12/31/2018	13	-190	-162	-157	N/A
9/30/2018	11	-178	-164	-157	N/A
6/30/2018	11	-172	N/A	-145	N/A
3/31/2018	11	-182	N/A	-147	N/A
12/31/2017	12	-177	N/A	-137	N/A
9/30/2017	11	-169	N/A	-118	N/A
6/30/2017	11	-157	N/A	-97	N/A
3/31/2017	9	-135	N/A	-77	N/A
12/31/2016	8	-121	N/A	-63	N/A
9/30/2016	8	-109	N/A	-58	N/A
6/30/2016	8	-88	N/A	-49	N/A
3/31/2016	8	-72	N/A	-41	N/A
12/31/2015	7	-49	N/A	-29	N/A
9/30/2015	6	-40	N/A	-28	N/A
6/30/2015	6	-30	N/A	-25	N/A
3/31/2015	5	-27	N/A	-23	N/A
12/31/2014	6	-29	N/A	-25	N/A
9/30/2014	6	-30	N/A	-24	N/A
6/30/2014	7	-32	N/A	-25	N/A
3/31/2014	6	-28	N/A	-21	N/A
12/31/2013	5	-27	N/A	-18	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DBVT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DBVT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: DBVT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DBVTの収益 ( 59.6% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: DBVTの収益 ( 59.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DBVTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

DBV Technologies 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain Compliance

Dbv Technologies Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe

DBV Technologies S.A. to Report Q2, 2024 Results on Jul 30, 2024

DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A)

DBV Technologies S.A., Annual General Meeting, May 16, 2024

DBV Technologies S.A. to Report Fiscal Year 2023 Results on Mar 07, 2024

DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

DBV Technologies S.A. to Present New Data at ACAAI 2023

DBV Technologies S.A. to Report Q3, 2023 Results on Oct 31, 2023

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Announces Executive Changes

Dbv Technologies S.A. Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies

DBV Technologies S.A. to Report First Half, 2023 Results on Jul 31, 2023

DBV Technologies Announces FDA Lifts Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Receives Feedback from the U.S. Food and Drug Administration in the Form of a Partial Clinical Hold on Its VITESSE Phase 3 Clinical Study

FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial

DBV Technologies S.A. Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M

DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty

DBV Technologies S.A. announced that it has received €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, Fairmount Funds Management LLC

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies Announces Positive Topline Results from Phase 3 Epitope Trial of Viaskin Peanut in Peanut-Allergic Toddlers

DBV Technologies S.A. to Report Q1, 2022 Results on May 02, 2022

DBV Technologies S.A. Provides Update on Investigational Viaskin Peanut

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

DBV Technologies S.A. to Report First Half, 2021 Results on Aug 02, 2021

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

DBV Technologies reports change in U.S. reporting status, cuts headcount

Hugh Sampson Decides to Step Down as Chief Scientific Officer of DBV Technologies, Effective December 1, 2020

DBV Technologies CSO Hugh Sampson to step down from role

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

DBV Technologies S.A. Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency

DBV Technologies shares rockets 85% as EMA approves Viaskin Peanut application

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘